Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,788
  • Shares Outstanding, K 64,473
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,050 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 531.66% (+78.11%)
  • Historical Volatility 70.05%
  • IV Percentile 98%
  • IV Rank 63.04%
  • IV High 788.27% on 02/13/26
  • IV Low 93.90% on 05/20/25
  • Expected Move (DTE 14) 0.75 (28.01%)
  • Put/Call Vol Ratio 3.09
  • Today's Volume 131
  • Volume Avg (30-Day) 762
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 39,790
  • Open Int (30-Day) 36,232
  • Expected Range 1.92 to 3.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 1
  • High Estimate $-0.06
  • Low Estimate $-0.06
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.55 +4.71%
on 04/02/26
3.50 -23.71%
on 03/10/26
-0.39 (-12.75%)
since 03/02/26
3-Month
2.55 +4.71%
on 04/02/26
4.17 -35.97%
on 01/05/26
-1.38 (-34.07%)
since 01/02/26
52-Week
1.12 +138.39%
on 04/04/25
7.13 -62.55%
on 12/17/25
+1.35 (+102.27%)
since 04/02/25

Most Recent Stories

More News
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

GALT : 2.67 (-0.37%)
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal...

GALT : 2.67 (-0.37%)
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension,...

GALT : 2.67 (-0.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT).  Such investors...

GALT : 2.67 (-0.37%)
Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin Therapeutics...

GALT : 2.67 (-0.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT).  Such investors...

GALT : 2.67 (-0.37%)
Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Galectin Therapeutics Inc. ("Galectin Therapeutics Inc.") (NASDAQ:...

GALT : 2.67 (-0.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT).  Such investors are...

GALT : 2.67 (-0.37%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT).  Such investors are...

GALT : 2.67 (-0.37%)
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”)...

GALT : 2.67 (-0.37%)

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

3rd Resistance Point 2.92
2nd Resistance Point 2.82
1st Resistance Point 2.74
Last Price 2.67
1st Support Level 2.57
2nd Support Level 2.48
3rd Support Level 2.40

See More

52-Week High 7.13
Fibonacci 61.8% 4.83
Fibonacci 50% 4.13
Fibonacci 38.2% 3.42
Last Price 2.67
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.